The size of the Asia Pacific In-vitro fertilization market is expected to worth USD 1.02 billion by 2025 from USD 0.44 billion in 2021, growing at a CAGR of 18.4% from 2021 to 2026.
In-vitro fertilization (IVF) involves the ovum's fertilization using laboratory settings followed by implantation into the uterus. In-vitro fertilization is also known as assisted reproductive technology. The process involves collecting matured healthy eggs and sperms from the partners or known or anonymous donors. These eggs get fertilized using laboratory reagents & media, and instruments. Fertilized eggs (embryos) are implanted into the uterus to continue the development of the embryo to the child. One cycle of in-vitro fertilization takes around 10-15 days. IVF is the most widely accepted method for fertility treatments in the clinical industry and helpful for couples with infertility problems, single mothers, and LGBT communities. The major product categories that assist in-vitro fertilization methods include reagents & media (such as embryo culture media, sperm processing media) and instruments (sperm separation system, cryptosystems).
The presence of a huge number of in-vitro fertilization clinics, growing adoption of in-vitro fertilization procedures, increasing fertility tourism, and rising government initiatives relating to the development of healthcare infrastructure in certain countries of Asia-Pacific (India, China, & Japan) are driving the growth of in-vitro fertilization market in Asia-Pacific region. Also, rising surrogacy, the growing rate of polycystic ovarian syndrome (PCOS), an increasing number of assisted reproductive technologies (ART) in Asian countries (Australia, New Zealand) are further stimulating the growth of the in-vitro fertilization market in the Asia-Pacific region.
However, ethical issues about gender selection, emotional & physical factors are restraining the growth of the in-vitro fertilization market in the Asia-Pacific region.
This research report on the Asia Pacific In-vitro fertilization market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By Instruments:
By Technology:
By End Users:
By Country: I
Based on instruments, the imaging systems segment commanded the largest share of the Asia-Pacific in-vitro fertilization market by instruments in 2020. The sperm separation systems segment is expected to grow at the highest CAGR during the forecast period 2020 to 2025.
Key participants dominating the In-Vitro Fertilization Market in the Asia Pacific region profiled in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Reagents and Media
5.2.1 Introduction
5.2.2 Embryo Culture Media
5.2.3 Cryopreservation Media 5.2.2.1 Autologous Cell-Based Products
5.2.4 Sperm Processing Media 5.2.2.2 Allogeneic Cell-Based Products
5.2.5 Ovum Processing Media
5.3 Instruments
5.3.1 Introduction
5.3.2 Imaging Systems
5.3.3 Sperm Separation Systems
5.3.4 Ovum Aspiration Pumps
5.3.5 Incubators
5.3.6 Micromanipulator Systems
5.3.7 Cryosystems
5.3.8 Other Instruments (Gas Analyzers, Laser Systems, Accessories)
5.4 Technology
5.3.1 Introduction
5.3.2 Intra-Cytoplasmic Sperm Injection (ICSI)
5.3.3 Pre-Implantation Genetic Diagnosis (PGD)
5.3.4 Frozen Embryo Transfer/Replacement (FET/FER)
5.3.5 Other Technologies
5.5 End Users
5.4.1 Introduction
5.4.2 Fertility and Surgical Centers
5.4.3 Hospitals and Research Laboratories
5.4.4 Cryobanks
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 CooperSurgical, Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cook Medical, Inc. (U.S.)
8.3 Irvine Scientific (U.S.)
8.4 Vitrolife AB (Sweden)
8.5 Thermo Fisher Scientific, Inc. (U.S.)
8.6 EMD Serono, Inc. (U.S.)
8.7 Genea Limited (Australia)
8.8 ESCO Micro Pte. Limited (Singapore)
8.9 IVFtech ApS (Denmark)
8.10 The Baker Company, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
